The PROTECT project. Introduction. Xavier Kurz Pharmacovigilance and Risk management Patient Health Protection Unit European Medicines Agency
|
|
|
- Cecily Holly Carr
- 8 years ago
- Views:
Transcription
1 The PROTECT project Introduction Xavier Kurz Pharmacovigilance and Risk management Patient Health Protection Unit European Medicines Agency Brookings Active Surveillance Implementation Council Meeting #2 The Brookings Institution, Washington DC November 18, 2010
2 PROTECT is receiving funding from the European Community's Seventh Framework Programme (FP7/ ) for the Innovative Medicine Initiative (
3 Partners Public Private Regulators: EMA (Co-ordinator) DKMA (DK) AEMPS (ES) MHRA (UK) GSK (Deputy Co-ordinator) Sanofi- Aventis Roche Novartis Academic Institutions: University of Munich FICF (Barcelona) INSERM (Paris) Mario Negri Institute (Milan) University of Groningen University of Utrecht Imperial College London University of Newcastle Upon Tyne SMEs: Others: WHO UMC GPRD IAPO CEIFE Pfizer Amgen Genzyme Merck Serono Bayer Schering Astra Zeneca Lundbeck NovoNordisk Outcome Europe PGRx
4 PROTECT Goal To strengthen the monitoring of benefit-risk of medicines in Europe by developing innovative methods to enhance early detection and assessment of adverse drug reactions from different data sources (clinical trials, spontaneous reporting and observational studies) to enable the integration and presentation of data on benefits and risks These methods will be tested in case studies.
5 Data collection from consumers WP4 Clinical trials Observational studies Electronic health records Spontaneous ADR reports Benefits Risks Signal detection WP3 Benefit-risk integration and representation WP5 Signal evaluation WP2 Validation studies WP6 Training and education WP7
6 WP 2: Framework for pharmacoepidemiological studies To: develop test disseminate Objectives: methodological standards for the: design conduct analysis of pharmacoepidemiological studies applicable to: different safety issues using different data sources
7 Work Package 2 WG1 Databases Conduct of 5 adverse event - drug pair studies in different EU databases Selection of 5 key adverse event - drug pairs Development of study protocols for all 5 pairs Compare results of studies Identify sources of discrepancies Antidepressants (incl. Benzodiazepines) -Hip Fracture Antibiotics - Acute liver injury Beta2 Agonists - Myocardial infarction Antiepileptics - Suicide Calcium Channel Blockers - Cancer
8 Work Package 3: Signal Detection Objective: To improve early and proactive signal detection from spontaneous reports, electronic health records, and clinical trials.
9 Work Package 3: Signal Detection Scope Develop new methods for signal detection in Individual Case Safety Reports. Develop methods and guidelines for signal detection and strengthening in Electronic Health Records. Evaluate signal detection based on Suspected Unexpected Serious Adverse Reactions from clinical trials. Recommendations for good signal detection practices.
10 Work Package 3: Sub-projects 1. Merits of disproportionality analysis 2. Structured database of known ADRs 3. Risk estimates from trials 4. Signal detection recommendations 5. Better use of existing ADR terminologies 6. Novel tools for grouping ADRs 7. Other information to enhance signal detection 8. Signal detection based on SUSARs 9. Subgroups and risk factors 10. Signal detection in Electronic Health Records 11. Drug-drug interaction detection 12. Duplicate detection
11 Work Package 4: Data collection from consumers Objectives: To assess the feasibility, efficiency and usefulness of modern methods of data collection including using web-based data collection and computerised, interactive voice responsive systems (IVRS) by telephone WP 4 will address limitations of data capture through conventional methods such as health care professionals and electronic health records.
12 Work Package 5: Benefit-risk Integration and Representation Objectives: To assess and test methodologies for the benefit-risk assessment of medicines To develop tools for the visualisation of benefits and risks of medicinal products Considerations given to: Perspectives of patients, healthcare prescribers, regulatory agencies and drug manufacturers From pre-approval to post-approval B-R assessment Individual and population-based decision-making Wave 1 case studies: Tysabri, Accomplia, Raptiva, Ketek
13 More information? Website:
European Medicines Agency s Postmarket Drug Safety Activities: Overview of PROTECT
European Medicines Agency s Postmarket Drug Safety Activities: Overview of PROTECT Xavier Kurz, Principal Scientific Administrator, Post- Authorisation, Pharmacovigilance and Risk Management Sector, European
A Case Study Using the BRAT Framework for Benefit Risk Assessment
A Case Study Using the BRAT Framework for Benefit Risk Assessment (1) A Generalization of the NNT/NNH concept Christoph Dierig Global Integrated Analysis, Bayer Pharma (2) Application and visualization
Medicines and Healthcare products Regulatory Agency
Medicines and Healthcare products Regulatory Agency 11 April 2016 Update on progress with the Joint Patient Safety and Vigilance Strategy Purpose: This paper provides the Board with an update on the Joint
Detailed guidance AEs reporting in clinical trials ( CT-3 ) Stefano Bonato, M.D. Pharmacovigilance Country Head Bayer HealthCare Pharmaceuticals
Detailed guidance AEs reporting in clinical trials ( CT-3 ) Stefano Bonato, M.D. Pharmacovigilance Country Head Bayer HealthCare Pharmaceuticals Pharmacovigilance costs 0.12%-0.22% of hospital admissions
EUROPEAN MEDICINES PRACTICES AND TOOLS AGENCY DRUG SAFETY
EUROPEAN MEDICINES AGENCY DRUG SAFETY PRACTICES AND TOOLS Henry Fitt, Kevin Blake, Xavier Kurz Pharmacovigilance & Risk Management European Medicines Agency, London Contents Eudravigilance & Signal Detection
Post-authorisation safety studies and the EU PAS Register
Post-authorisation safety studies and the EU PAS Register Xavier Kurz European Medicines Agency EMA, 11 October 2012 An agency of the European Union Content of the presentation 1. PASS: definition and
SALUS: Enabling the Secondary Use of EHRs for Post Market Safety Studies
SALUS: Enabling the Secondary Use of EHRs for Post Market Safety Studies May 2015 A. Anil SINACI, Deputy Project Coordinator SALUS: Scalable, Standard based Interoperability Framework for Sustainable Proactive
Stakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes
Stakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes Dr Anya Sookoo, Expert Inspector, Inspections, Enforcement & Standards Division,
COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/044/99-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT
How To Create A Pediatric Health Care Database In The European Union
GRiP Global Research in Paediatrics Pediatric Pharmacoepidemiology Platform Miriam Sturkenboom, Erasmus University Jan Bonhoeffer, Brighton Collaboration Foundation On behalf of the GRiP Network of Excellence
Strategy and pilot phase for patient registries
Strategy and pilot phase for patient registries Draft still under discussion Industry Stakeholder Platform - Operation of EU Pharmacovigilance Legislation 12 January 2015 Xavier Kurz, Head of Monitoring
Risk Management in the Pharmaceutical Industry. Elena Apetri, Global Medical Safety Surveillance Schering AG
Risk Management in the Pharmaceutical Industry Elena Apetri, Global Medical Safety Surveillance Schering AG Topics Environment Safety Risk Management Guidance Safety RM Systems Signal detection and evaluation
MedDRA in pharmacovigilance industry perspective
MedDRA in pharmacovigilance industry SFDA ICH MedDRA Workshop, Beijing, 13 14 May 2011 Christina Winter, MD, FFPM Medical director GlaxoSmithKline R&D / ICH MedDRA Management Board 2011 ICH International
GUIDELINE ON THE SUBMISSION OF RISK MANAGEMENT PLAN DOCUMENTS
APPENDIX GUIDELINE ON THE SUBMISSION OF RISK MANAGEMENT PLAN DOCUMENTS This document is intended to provide guidance on the submission of risk management plan (RMP) documents in support of NDA, GDA and
Medicine and Big Data
Medicine and Big Data A happy marriage? David Madigan Department of Sta8s8cs Columbia University & OMOP Evidence- Based Medicine as against??? How does the combina8on of Clinical Judgment and Evidence-
Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595
Transparency Market Research Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Buy Now Request Sample Published Date:
Executive Summary for deliverable D7.1: Establish specification for data acquisition and standards used including a concept for local interfaces
Electronic Health Records for Clinical Research Executive Summary for deliverable D7.1: Establish specification for data acquisition and standards used including a concept for local interfaces Project
Guideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/541760/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration
OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP
OBSERVATIONAL Opportunities for Signal Detection in an Active Surveillance System Andrew Bate Pfizer, Senior Director, Analytics Team Lead Epidemiology OMOP January 2011 Symposium Contents Background Signal
Sharing Industry Clinical Trial Data: Improving Public Health While Maintaining the Oversight Relationship Between Regulator and Sponsor
Sharing Industry Clinical Trial Data: Improving Public Health While Maintaining the Oversight Relationship Between Regulator and Sponsor Steven Snapinn SCT/QSPI/FDA Workshop Innovations in the Science
Guidance on adverse drug reactions
Guidance on adverse drug reactions Classification of adverse drug reactions Adverse drug reactions are frequently classified as type A and type B reactions. An extended version of this classification system
EudraVigilance stakeholder change management plan
26 October 2015 EMA/797114/2014 Information Management Division Consultation of Project Maintenance Group 1 15 July 2015 Consultation of Eudravigilance Expert Working Group 23 September 2015 Consultation
Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries
Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries April 16, 2010 Oracle is currently reviewing the existing Phase Forward product roadmap and will be
Embedding patient centricity Understanding the role of real-world evidence in global market access strategies. Copyright 2014 Quintiles
Embedding patient centricity Understanding the role of real-world evidence in global market access strategies Copyright 2014 Quintiles Agenda Introduction Real-world evidence: Increasing access to innovative
EMEA RM DRAFT GUIDANCE ISPE RESPONSE 1
EMEA RM DRAFT GUIDANCE ISPE RESPONSE 1 October 4, 2005 Guideline on Risk Management Systems for Medicinal Products for Human Use DRAFT London, 6 September 2005. This guideline will be included as chapter
Risk Management Plan (RMP) on Biologicals and NCE
Transformation towards a New Regulatory Paradigm Risk Management Plan (RMP) on Biologicals and NCE Junko SATO International Coordination Officer PMDA, Japan 1 2 Pharmaceuticals and Medical Devices Agency
EMA and Progressive Multifocal Leukoencephalopathy.
EMA and Progressive Multifocal Leukoencephalopathy. ENCePP Plenary, London 23 November 2011 Presented by: Henry Fitt Head of Coordination & Networking, Pharmacovigilance & Risk Management An agency of
Safety Risk Management Company Perspective
Safety Risk Management Company Perspective Akihisa Harada, MD, Ph.D VP, Development Japan Pfizer Japan Inc. R&D Head Club Agenda REMS in FDAAA Safety Risk Management throughout a Drug s Lifecycle Risk
Competentes en Medicamentos
VIII Encuentro de Autoridades Competentes en Medicamentos de los Países Iberoamericanos (EAMI) 12-14 de Mayo 2010 Madrid MARTIN TERBERGER Jefe de la Unidad de Productos Farmacéuticos Nuevas iniciativas
Practical experiences of risk minimisation
Practical experiences of risk minimisation Ciara Kirke Health Services Executive Quality Improvement Division Ireland 16 th September, 2015 Sources of harm with medicines Drug, medicinal product, packaging
Biotech Concerto #3. European Clinical Trial Environment
Biotech Concerto #3 European Clinical Trial Environment December 2008 Index EU Directive EU Approval System European Authority: EMEA The Guidance Documents Route Map Challenges EMEA Organization Chart
Guideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/541760/2011 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration with Member
EFPIA Good Practice Revision 1, October 2014
EFPIA Good Practice Revision 1, October 2014 Reducing Risk of Drug Products Shortages Introduction Authorities, industry and healthcare providers have a responsibility to ensure a modern and sustainable
FDA s Sentinel Initiative: Current Status and Future Plans. Janet Woodcock M.D. Director, CDER, FDA
FDA s Sentinel Initiative: Current Status and Future Plans Janet Woodcock M.D. Director, CDER, FDA FDA Amendments Act of 2007 Section 905: Active Postmarket Risk Identification and Analysis Establish a
EphMRA Adverse Event Reporting Guidelines 2015
EphMRA Adverse Event Reporting Guidelines 2015 Based upon the Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products European
EphMRA Adverse Event Reporting Guidelines 2013
EphMRA Adverse Event Reporting Guidelines 2013 Based upon the Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products European
The EU Clinical Trial Regulation A regulator s perspective
5 The EU Clinical Trial A regulator s perspective Author Martyn Ward, Group Manager, Licensing, Medicines and Healthcare products Regulatory Agency (MHRA), UK. Keywords Clinical Trial Directive (the Directive);
Pharmacovigilance and the Internet: A Call for Change
Pharmacovigilance and the Internet: A Call for Change A white paper from the ABPI Pharmacovigilance Expert Network 13 June 2011 Page 2 of 6 Pharmacovigilance and the Internet: A Call for Change (ABPI)
Guidance notes on collection of drug safety information by employees and agents of pharmaceutical companies
Guidance notes on collection of drug safety information by employees and agents of pharmaceutical companies March 2013 Guidance notes on collection of drug safety information by employees and agents of
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT. Guideline on Risk Management Systems for Medicinal Products for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 6 September 2005 Doc. Ref. EMEA/CHMP/96268/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT Guideline on Risk Management
Risk Management Plan (RMP) Guidance (Draft)
Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour
EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART
EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART Framework Labs generate data that are used to make decisions on the safety and efficacy of medicinal products; consequently,
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare
Causality Assessment in Practice Pharmaceutical Industry Perspective. Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd.
Causality Assessment in Practice Pharmaceutical Industry Perspective Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd., Basel Disclaimer: The opinions expressed in this presentation are
Synergies between ENCePP and Health Technology Assessment. Anne Solesse, Post-registration studies department, HAS, France
Synergies between ENCePP and Health Technology Assessment Anne Solesse, Post-registration studies department, HAS, France Joint Action A total of 34 government appointed organisations from 23 EU Member
Standard Operating Procedure on Training Requirements for staff participating in CTIMPs Sponsored by UCL
Page 1 of 10 Standard Operating Procedure on Training Requirements for staff participating in CTIMPs Sponsored by UCL SOP ID Number: Effective Date:01/08/2012 Version Number & Date of Authorisation: V02,
Strategy & Policy. 27 January 2004. Michael Tremblay PhD. Tremblay Consulting. mike@tremblay-consulting.biz
Strategy & Policy Submission to the Consultation by the National Patient Safety Agency on patient safety and electronic prescribing (and other health information) systems 27 January 2004 Michael Tremblay
Medicine Safety Glossary
The following definitions are provided as a resource to supplement the information provided in the Medicine Safety Education section of the Pfizer.com Web site; they are not intended as a comprehensive
EU-ADR Healthcare Database Network vs. Spontaneous Reporting System Database: Preliminary Comparison of Signal Detection
Patient Safety Informatics V. Koutkias et al. (Eds.) IOS Press, 2011 2011 The authors and IOS Press. All rights reserved. doi:10.3233/978-1-60750-740-6-25 25 EU-ADR Healthcare Database Network vs. Spontaneous
Pivot Park Screening Centre participates in novel 196 million pan-european drug discovery platform
PRESS RELEASE Pivot Park Screening Centre participates in novel 196 million pan-european drug discovery platform Pivot Park Screening Centre in Oss will play an important role in a new pan-european drug
Risk Assessment and Management: A Regulatory Lawyer s Perspective
Risk Assessment and Management: A Regulatory Lawyer s Perspective Presented By: Alan G. Minsk Partner and Leader, Food and Drug Practice Team Arnall Golden Gregory LLP 171 17 th Street, NW, Suite 2100
YOUR GATEWAY TO. EXPERIENCE, quality & FLEXIBILITy
YOUR GATEWAY TO EXPERIENCE, quality & FLEXIBILITy DATA MANAGEMENT SERVICES The quality of your data defi ne the success of your trial, therefore proper handling of data is fundamental. Our Data Management
The Respective Roles of Controlled Clinical Trials and Cohort Monitoring Studies in the Pre- and Postmarketing Assessment of Drugs
PHARMACOLOGIE CLINIQUE Thérapie 2005 Juil-Août; 60 (4): 345-349 0040-5957/05/0004-0345/$34.95/0 2005 Société Française de Pharmacologie The Respective Roles of Controlled Clinical Trials and Cohort Monitoring
Potential for Apps in Pharmaceutical Development. Steve Hutson Co-founder Virtual PV
Potential for Apps in Pharmaceutical Development Steve Hutson Co-founder Virtual PV Potential for Apps in Pharmaceutical Development Steve Hutson Co-founder Virtual PV Potential for Apps in Pharmaceutical
Guidance notes. for Patient Safety and Pharmacovigilance in Patient Support Programmes
Guidance notes for Patient Safety and Pharmacovigilance in Patient Support Programmes 9 May 2011 Approval Status Authors The ABPI Pharmacovigilance Expert Network Change History N/A Approval Date 9 May
ICH guideline E2C (R2) Periodic benefit-risk evaluation report (PBRER)
April 2012 EMA/CHMP/ICH/544553/1998 Committee for medicinal products for human use (CHMP) ICH guideline E2C (R2) Periodic benefit-risk evaluation report (PBRER) Step 3 Transmission to CHMP 16 April 2012
THE BIOTECH & PHARMACEUTICAL INDUSTRY
THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues
Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291
Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Steps Taken for Assessment Page 13 Summary of Product Characteristics
One-year report on human medicines pharmacovigilance tasks of the European Medicines Agency
8 April 2014 EMA/171322/2014 Pharmacovigilance Department One-year report on human medicines pharmacovigilance tasks of the European Medicines Agency Reporting period: 2 July 2012 to 1 July 2013 7 Westferry
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON RISK MANAGEMENT SYSTEMS FOR MEDICINAL PRODUCTS FOR HUMAN USE
European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use London, 14 November 2005 Doc. Ref. EMEA/CHMP/96268/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE
Identity Management & Digital Signatures in the BioPharmaceutical Industry John Hendrix; Program Director CTST 2009
Identity Management & Digital Signatures in the BioPharmaceutical Industry John Hendrix; Program Director CTST 2009 2009 SAFE-BioPharma Association Overview Conducting Business in the Electronic World
Guidance notes on the management of adverse events and product complaints from digital media
Guidance notes on the management of adverse events and product complaints from digital media Guidance notes on the management of adverse events and product complaints from digital media ABPI Pharmacovigilance
The German Clinical Trials Directive (CTD) and Its Impact on Cancer Research
Supporting research, protecting patients Cancer Research UK s recommendations to reform the Clinical Trials Directive Supporting patients, protecting research About Cancer Research UK Contents Executive
DESCRIPTION OF THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004
DESCRIPTION OF THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 Page 1 of 17 TABLE OF CONTENTS INTRODUCTION 4 EXECUTIVE SUMMARY 4 PUBLIC HEALTH BENEFITS 5 Good clinical practice 5 Good manufacturing
Anatomical Therapeutic Chemical (ATC) classification and the Defined Daily Dose (DDD): principles for classifying and quantifying drug use
Anatomical Therapeutic Chemical (ATC) classification and the Defined Daily Dose (DDD): principles for classifying and quantifying drug use DRAFT Yong Chen Merck, Whitehouse Station, NJ USA Disclosure Author
Final report of the ECDC Management Board Working Group on New Business Models and Financing of Large-scale EU Level Activities.
Final report of the ECDC Management Board Working Group on New Business Models and Financing of Large-scale EU Level Activities 26 November 2014 Contents Report of the ECDC Management Board Working Group
The European regulatory system for medicines and the European Medicines Agency
The European regulatory system for medicines and the European Medicines Agency A consistent approach to medicines regulation across the European Union An agency of the European Union This booklet is intended
Requirements for Drug Information Centres
FIP Pharmacy Information Section Requirements for Drug Information Centres Summary All countries should provide drug information services either independently or as part of a regional network. The service
Interferon beta products: risk of thrombotic microangiopathy and nephrotic syndrome
Monday 1 st September, 2014 Interferon beta products: risk of thrombotic microangiopathy and nephrotic syndrome Dear Healthcare Professional, The Medicines and Healthcare Products Regulatory Agency in
OUTCOMES RESEARCH USING A LEARNING HEALTH SYSTEM: PROMISE & PITFALLS
OUTCOMES RESEARCH USING A LEARNING HEALTH SYSTEM: PROMISE & PITFALLS Richard L. Tannen, M.D. University of Pennsylvania Perelman School of Medicine KFF director of Medical research u More than a decade
PG Diploma in Clinical Research, Pharmacovigilance, Regulatory and Clinical Data Management
PG Diploma in Clinical Research, Pharmacovigilance, Regulatory and Clinical Data Management Contact: +91 9886735658, 080 28411665 ext 5103 Email: crtraining@avesthagen.com PG Diploma In Clinical Research,
Electronic exchanges of individual case safety reports (ICSRs) with ANSM (National Agency of Medicine and Health Product safety)
Pharmacovigilance information for pharmaceutical companies Electronic exchanges of individual case safety reports (ICSRs) with ANSM (National Agency of Medicine and Health Product safety) This document
PHV- 4 version 1 ELECTRONIC ADVERSE DRUG REACTION REPORTING
PHV- 4 version 1 ELECTRONIC ADVERSE DRUG REACTION REPORTING This guideline supersedes guideline PHV 4 as of September 16 2008. 1. Introduction and general provisions 1.1 Purpose of the guideline The guideline
Questions & answers on signal management
23 October 2015 EMA/261758/2013 Inspections and Human Medicines Pharmacovigilance Division This document addresses a number of questions which stakeholders, in particular marketing authorisation holders
Accenture Accelerated R&D Services:
Accenture Life Sciences Rethink Reshape Restructure for better patient outcomes Accenture Accelerated R&D Services: Pharmacovigilance Services Overview At our company, we are focused on improving lives
Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER
Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER LT Andrew Fine, Pharm.D., BCPS Safety Evaluator Division of Pharmacovigilance Office of Pharmacovigilance and Epidemiology
Clinical trials: from European perspective to National implementation. CTFG / FAMHP / pharma.be. Brussels, 19 November 2010
Clinical trials: from European perspective to National implementation CTFG / FAMHP / pharma.be Brussels, 19 November 2010 Safety in clinical trials: From detection to decision How safety events are captured
Omeprazole 20 mg gastro-resistant tablets PL 14017/0277
Omeprazole 20 mg gastro-resistant tablets PL 14017/0277 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 11 Steps Taken After Initial Authorisation
Overview of the EHR4CR project Electronic Health Record systems for Clinical Research
Overview of the EHR4CR project Electronic Health Record systems for Clinical Research Dipak Kalra UCL on behalf of the EHR4CR Consortium ENCePP Plenary Meeting, 3rd May 2012, London The problem (as addressed
Over-prescribing Excessive doses/duration of medicines Lacking indication. Mis-prescribing Unfavourable choice of medicine, dose, or duration
Inappropriate prescribing: STOPP-START criteria Clara Drenth-van Maanen, MD Clinical pharmacologist Risks outweighing benefits Inappropriate prescribing Over-prescribing Excessive doses/duration of medicines
Risk Management Plan - Bayer Experience :
Risk Management Plan - Bayer Experience : Organization & Processes Najoua ADYEL Pharmacovigilance Country Head Maghreb Introduction: Pharmacovigilance toward maturity 50 s and 60 s: from nothing to reacting
Oracle Health Sciences Suite of Life Sciences Solutions
Oracle Health Sciences Suite of Life Sciences Solutions Integrated Solutions for Global Clinical Trials Oracle Health Sciences provides the world s broadest set of integrated life sciences solutions, enabling
School of Pharmacy TEMPLE UNIVERSITY
School of Pharmacy TEMPLE UNIVERSITY Regulatory Affairs and Quality Assurance Graduate Program Te mple Unive rsity School of Pharmacy Re gulatory Affairs and Quality Assurance Graduate Program 4 25 Comme
INTERNATIONAL PHARMACEUTICAL PRIVACY CONSORTIUM COMMENTS IN RESPONSE TO THE CALL FOR EVIDENCE ON EU DATA PROTECTION PROPOSALS
INTERNATIONAL PHARMACEUTICAL PRIVACY CONSORTIUM COMMENTS IN RESPONSE TO THE CALL FOR EVIDENCE ON EU DATA PROTECTION PROPOSALS I. INTRODUCTION The International Pharmaceutical Privacy Consortium (IPPC)
New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Late-Breaking Science at ESC Congress 2015: New Real-World Evidence Reaffirms
170 Current Drug Safety, 2012, 7, 170-175
170 Current Drug Safety, 2012, 7, 170-175 Implemented Data Mining and Signal Management Systems on Spontaneous Reporting Systems Databases and their Availability to the Scientific Community - A Systematic
Optimizing Safety Surveillance During Clinical Trials Using Data Visualization Tools
Optimizing Safety Surveillance During Clinical Trials Using Data Visualization Tools Laura McKain, M.D., Medical Director, Pharmacovigilance; Tammy Jackson, Director, Preclarus Development, Clinical Innovation;
Guideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/876333/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions Draft finalised by the Agency in collaboration with Member States 7 February 2012 Definitions
REGULATORY REQUIREMENTS OF PHARMACOVIGILANCE SYSTEM AND ITS COMPARISON IN INDIA AND USA
ISSN: 2230-7346 Krupa C. Thula et al. / JGTPS / 6(1)-(2015) 2351 2356 (Review Article) Journal of Global Trends in Pharmaceutical Sciences Journal home page: www.jgtps.com REGULATORY REQUIREMENTS OF PHARMACOVIGILANCE
The Evolution of Data Platforms in IMI. Anthony Rowe, Janssen R&D IT 08 April 2016 Med-e-Tel Luxembourg
The Evolution of Data Platforms in IMI Anthony Rowe, Janssen R&D IT 08 April 2016 Med-e-Tel Luxembourg Three trends in technology today Ubiquity of the Internet Three trends in technology today Ubiquity
Continuing education for community pharmacists in Denmark the case of Master of Drug Management
Continuing education for community pharmacists in Denmark the case of Master of Drug Management Birthe Søndergaard Associate Professor Department of Pharmacology and Pharmacotherapy, Section of Social
In the largest and perhaps the most ambitious collaborative
FEATURES THE BIRTH OF TRANSCELERATE BIOPHARMA, INC. Revolution in Clinical Research Partnerships by Dalvir Gill and Garry Neil In the largest and perhaps the most ambitious collaborative effort ever initiated
Guideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/827661/2011 Guideline on good pharmacovigilance practices (GVP) Module IX Signal management Draft finalised by the Agency in collaboration with Member States and submitted to ERMS FG 19
What is NEWMEDS? EFPIA companies: H Lundbeck A/S, Abbvie, AstraZeneca AB, Eli Lilly and
Pre-competitive gains from data sharing across sponsors: the power of big data and colloboration NewMeds Working group: Leads: Jonathan Rabinowitz, Bar Ilan University; Ivo Caers, Janssen Research & Development;
The information contained in these slides is for general purposes only and presents the state of knowledge at November 30, 2011
1 The information contained in these slides is for general purposes only and presents the state of knowledge at November 30, 2011 No rights can be derived from this information The Medicines Evaluation
Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL)
![Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL)](/thumbs/26/8616095.jpg "Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL)")
PRESS RELEASE Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL) Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases
STANDARD OPERATING PROCEDURE FOR RESEARCH. 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol
Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol
EU PAS Register Guide
29 March 2016 EMA/613603/2012 (currently ENCePP E-Register of Studies) The EU PAS Register is temporarily hosted on the ENCePP website www.encepp.eu 1. Introduction... 2 2. ENCePP E-Register as a temporary
Adopted by CHMP in November 2006. Revision 1.0 adopted by CHMP on 25 June 2009
European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use London, 25 June 2009 Doc. Ref: EMEA/359381/2009 CHMP Recommendations for the Pharmacovigilance Plan as part of the Risk
REMS: The New Reality
Kuyler Doyle, Principal Consultant, Campbell Alliance Jay Jauregui, Senior Practice Executive, Trade and Distribution Practice Gary Tyson, Senior Vice President, Clinical Development and Medical Affairs